Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Edoxaban Can Cover 80% of NOAC-Targeted Patients despite Restricted Use: US Commercial Chief
February 18, 2015
- Ono, Dako to Jointly Develop Companion Diagnostic Test for Opdivo
February 18, 2015
- MSD, Sanofi to Copromote RotaTeq, Heptavax in Japan
February 18, 2015
- Takeda to Terminate Asian PIII Study for Motesanib
February 18, 2015
- Nichi-Iko to Exclusively Market Plavix Authorized Generics
February 17, 2015
- Lenvatinib Obtains World’s 1st Approval in US: Eisai
February 17, 2015
- Banzel Approved in US for Pediatric Use: Eisai
February 17, 2015
- Otsuka Holdings Weighs Staff Realignment as Abilify Patent Expiry Looms
February 16, 2015
- Merck Serono to Independently Promote Erbitux from May
February 16, 2015
- Otsuka Holdings Promotes Vice Chairman Ichiro Otsuka to Chairman on March 27
February 16, 2015
- Meiji Seika Pharma Completes Acquisition of Outstanding Shares of Medreich
February 16, 2015
- Antithrombotic Agent Sales Up 7.4% in 2014 on Buoyant Plavix, Xarelto: IMS
February 13, 2015
- GSK Eyes Transfer of Oncology Teams to Novartis from March
February 13, 2015
- Japan Pharma Market Grows 1.4% in 2014, Plavix Retains Crown in Sales Ranking: IMS
February 13, 2015
- AbbVie Files NDA for Chronic Hepatitis C Treatment in Japan
February 13, 2015
- Otsuka Pharma Pres. Iwamoto Dies at 54, Holding Firm CEO to Take Over
February 12, 2015
- Hypertension Most Commonly Treated Disease in Japan: Survey
February 12, 2015
- JCR Begins PI Study of Biosimilar for Fabry’s Disease Therapy
February 12, 2015
- Ixazomib, Successor to Velcade, Improved PFS in Interim Analysis of PIII Study: Takeda
February 12, 2015
- Once-Monthly Oral Ibandronate Filed for Approval in Japan: Chugai, Taisho
February 12, 2015
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…